Physician profile
James K Speed
NPI 1811059660
$2,301.73
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $213 · 2021: $319 · 2022: $596 · 2023: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.36 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.08 | 2019-2023 | Jardiance |
| Insulet Corporation | $390.85 | 2019-2023 | Omnipod |
| Lilly USA, LLC | $184.20 | 2019-2022 | |
| Corcept Therapeutics | $170.92 | 2021 | |
| Mannkind Corporation | $126.29 | 2022 | |
| Companion Medical, INC. | $37.59 | 2019 | |
| Tandem Diabetes Care, INC. | $37.42 | 2019-2020 | |
| Medtronic Minimed, INC. | $25.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.23 | 2019 | |
| Senseonics, Incorporated | $19.00 | 2019 | |
| Shire North American Group INC | $18.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.89 | 2019 | |
| Ibsa Pharma INC. | $17.82 | 2020 | |
| Abbott Laboratories | $16.10 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $15.37 | 2019 | |
| Lifescan, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Speed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.